United Kingdom news - the latest biotech news from Labiotech.eu

Home United Kingdom Page 8

Latest Posts

Roquefort Therapeutics

News and Trends 1 Jan 2023

Watch: Roquefort Therapeutics at BioFIT

Roquefort Therapeutics is a biotech company developing first-in-class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth […]

January 1, 2023 - 1 minutemin - By Jim Cornall

heart surgery

News and Trends 21 Dec 2022

Stem cell plasters could revolutionize heart surgeries

Researchers at the University of Bristol in the U.K. funded by the British Heart Foundation (BHF) have developed ‘stem cell plasters’ to revolutionize the way surgeons treat children living with congenital heart disease, so they don’t need as many open-heart operations. Heart defects are the most common type of anomaly that develop before a baby […]

December 21, 2022 - 4 minutesmins - By Jim Cornall

green bioactives Anastasiia Slynko

Startup Scout 19 Dec 2022

Green Bioactives grows medicines in plant cells

Though plants may hold the key to new, effective medicines, sourcing these compounds sustainably is difficult. Green Bioactives devises eco-friendly ways to produce plant-derived drugs via plant cell cultures. For decades, the pharmaceutical industry has designed synthetic small molecule drugs and manufactured them via chemical synthesis. While this approach provides an easy way to supply […]

December 19, 2022 - 4 minutesmins - By Jonathan Smith

Beyond Biotech podcast 26

News and Trends 16 Dec 2022

Beyond Biotech podcast 26: CellCentric, MicrofluidX, Potter Clarkson

This week, we have three guests. We have conversations with Antoine Espinet, CEO of MicrofluidX; Will West, CEO of CellCentric; and Sara Holland, patent attorney at Potter Clarkson. MicrofluidX raises £3.3M to develop advanced therapy manufacturing platform MicrofluidX (MFX), a U.K. based provider of next-generation bioreactors for cell research and manufacturing, today announces £3.3 million […]

December 16, 2022

Huntington's Disease

News and Trends 16 Dec 2022

Alchemab Therapeutics receives £1.7M grant to work on therapy for Huntington’s disease

Alchemab Therapeutics has been awarded a grant of £1.7 million ($2 million) from Innovate UK’s Biomedical Catalyst (BMC) 2022 funding competition to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease. Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical studies to progress its panel of antibodies towards first […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

financing

News and Trends 14 Dec 2022

STORM Therapeutics closes $30M Series B financing

STORM Therapeutics Ltd., which is working on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, has successfully completed a $30 million Series B financing round. The financing was co-led by existing investors M Ventures, Pfizer Ventures, Taiho Ventures LLC, Cambridge Innovation Capital (CIC) and new investors […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

ADVERTISEMENT

3875 05 Laboratory Interior Final 021222

News and Trends 14 Dec 2022

Planning application submitted for Europe’s largest life sciences building

Canary Wharf Group (CWG) and Kadans Science Partner are submitting a detailed planning application for a commercial health and life sciences building at Canary Wharf, London. The companies said the 23-story 823,000 sq ft tower will be Europe’s largest and most technologically advanced life sciences facility. Energy efficiency is at the forefront of the building’s […]

December 14, 2022 - 4 minutesmins - By Jim Cornall

healthcare technology

News and Trends 14 Dec 2022

Tachmed aiming to make healthcare more accessible

Tachmed is looking to transform access to healthcare through technology. The company’s CEO, Paul Christie, tells us how. What is the driving force behind Tachmed? What motivated you to work towards transforming digital diagnostics technology? It was during my private equity career that the idea of Tachmed was born. I was with a team running […]

December 14, 2022 - 4 minutesmins - By Jim Cornall

septic shock sepsis

News and Trends 13 Dec 2022

Blood clotting research holds hope for sepsis

Researchers from the University of Birmingham in the U.K., who identified a novel mechanism for platelet activation in pathogenic blood clotting (thrombosis), are now turning their attention to sepsis. Identified by associate professor Julie Rayes and Martina Colicchia from the Birmingham Platelet Group, and described in a recent paper in Blood, this previously unknown axis […]

December 13, 2022 - 2 minutesmins - By Jim Cornall

AI rare disease diagnostics Elena Resko

Opinion 12 Dec 2022

Artificial intelligence: a new era in rare genetic disease diagnosis

Despite the onset of the genomics era, rare disease diagnosis remains a challenge. Nostos Genomics’ co-founder, Rocío Acuña Hidalgo, and chief operating officer, Ansgar Lange, shed light on how artificial intelligence (AI) could fill in the gaps. It is estimated that 300 million people worldwide are affected by rare diseases and around 80% of these […]

December 12, 2022 - 6 minutesmins - By External Contributor

breast cancer treatment

News and Trends 9 Dec 2022

New targeted drug shows benefit against breast cancer in first phase III trial

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most common type of breast cancer. The findings, presented […]

December 9, 2022 - 7 minutesmins - By Jim Cornall

ebola vaccine merck janssen

News and Trends 9 Dec 2022

The Native Antigen Company expands infectious disease portfolio

The Native Antigen Company (part of LGC Clinical Diagnostics), today announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP). The addition of this latest recombinant protein expands the company’s comprehensive portfolio of antigens and antibodies for infectious diseases and has been designed to support immunoassay and vaccine development. The Native Antigen […]

December 9, 2022 - 2 minutesmins - By Liza Laws

ADVERTISEMENT